Recording-2025-01-28 zoom LEC blood clots

Hemostasis Overview

Hemostasis is the complex process that prevents and stops bleeding, ultimately leading to the formation of a stable blood clot. It consists of several interrelated steps that ensure rapid responses to vascular injury.

Steps of Hemostasis

  • Vascular Spasm:

    • Immediately after a blood vessel is injured, smooth muscle fibers in its walls contract, resulting in vasoconstriction. This vascular spasm reduces blood flow and blood loss while also promoting the next step in hemostasis.

  • Platelet Plug Formation:

    1. When the vessel is damaged, the underlying collagen fibers are exposed.

    2. von Willebrand factor (vWF) binds to these collagen fibers and platelets.

    3. Platelets adhere to the site of injury and become activated, changing shape to become spiky, increasing the surface for aggregation.

    4. Degranulation occurs, wherein activated platelets release granules containing:

      • ATP (Adenosine Triphosphate): Promotes further platelet activation.

      • ADP (Adenosine Diphosphate): Attracts more platelets to the site.

      • Serotonin: Causes vasoconstriction to minimize blood loss.

      • Calcium: Crucial for various coagulation factors to function.

      • Clotting Factors: Various proteins that facilitate the coagulation cascade.

    5. The accumulation of more platelets, propelled by the positive feedback mechanism, creates a platelet plug that temporally seals the vessel injury.

  • Coagulation:The coagulation phase involves a cascade of reactions that solidify the platelet plug into a stable clot.

    • Intrinsic Pathway: Initiated by damage to blood vessels and involves factors already present in the bloodstream. It is slower but involves more complex steps, including the activation of factor 12, 11, 9, and 10, leading to the common pathway.

    • Extrinsic Pathway: Triggered by tissue factor (TF) released from damaged tissues. It proceeds rapidly, activating factor 7 and leading to factor 10 activation.

    • Common Pathway: Activated factor 10 (Xa) catalyzes the conversion of prothrombin (factor 2) into thrombin (factor 2a). Thrombin then converts fibrinogen (factor 1) into fibrin, providing a mesh-like structure that stabilizes the clot.

  • Clot Retraction:Platelets contain actin and myosin filament proteins which, upon contraction, draw the edges of the wound closer together, expelling excess serum from the clot. This results in a tighter, stronger plug. The yellowish fluid observed on bandages after injury arises from this process.

  • Thrombolysis:After the vessel is sufficiently healed, the fibrin clot must be removed — a process called thrombolysis. Tissue Plasminogen Activator (TPA) is released from the endothelial cells; it converts plasminogen to plasmin, which digests fibrin into smaller fragments, promoting clot dissolution.

  • Prevention of Unwanted Clotting:To avoid unnecessary clot formation, endothelial cells release prostacyclin and nitric oxide (NO), which inhibit platelet activation and aggregation. Additionally, anticoagulants, such as Heparin and Coumadin, assist in controlling clotting, particularly in patients at risk for thrombus formation.

Types of Clotting Disorders

  • Hemophilia:Genetic disorders that result in deficiencies of specific clotting factors, leading to excessive bleeding. Hemophilia A and B are the most common forms, linked to deficiencies in factor 8 and factor 9 respectively.

  • Hypercoagulable States:These conditions like deep vein thrombosis (DVT) are characterized by an increased propensity for blood clotting, leading to thrombus (blood clot) or embolus (traveling clot) formation. DVT is particularly dangerous due to the risk of pulmonary embolism.

Medications for Clot Management

  • Thrombolytic Agents:Such as TPA and Urokinase are used to break down existing blood clots when there is a clinical need, like in cases of heart attacks or strokes.

  • Anticoagulants:Common agents include Heparin (which is administered through injections) and Coumadin (oral). Newer anticoagulants like Apixaban (Eliquis) and Rivaroxaban (Xarelto) are more targeted and do not necessitate dietary restrictions.

Special Cases

  • Erythroblastosis Fetalis:An immunological condition resulting from Rh incompatibility, where an Rh-negative mother produces antibodies against the Rh-positive blood of her fetus, leading to hemolysis.

  • RhoGAM:A medication given to Rh-negative mothers during pregnancy and right after delivery to prevent the formation of harmful antibodies against Rh-positive blood.